Epidemiology, the Impact of COVID-19, and the Mycological Approach in Invasive Mold Infection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Invasive fungal infections are a significant health challenge worldwide. Although invasive yeast infections are more prevalent, invasive mold infections (IMIs), such as Aspergillus spp., Mucorales, and Fusarium spp., are rising. The increase in IMIs is attributed to various factors, such as transplantation, aggressive treatments, invasive medical devices, and the emergence of new at-risk populations, such as patients with influenza and SARS-CoV-2-associated aspergillosis. The European Organization for Research and Treatment of Cancer and the Mycosis Study Group initially provided definitions based on host and clinical factors, including radiological findings and mycological evidence. The recent 2020 updates of the definitions state that a case confirmed by microscopy, histopathology, and culture from a sterile site is "proven"; however, regarding mycological criteria, this guideline introduced revised thresholds for the galactomannan assay based on sample types, excluded the 1,3-β-D-glucan detection assay, and acknowledged positive Aspergillus polymerase chain reaction tests from serum, plasma, or bronchoalveolar lavage fluid. The current diagnostic approach improves the accuracy and timeliness of diagnosing fungal infections and facilitates more effective patient management.
Abstract
Invasive fungal infections are a significant health challenge worldwide. Although invasive yeast infections are more prevalent, invasive mold infections (IMIs), such as Aspergillus spp., Mucorales, and Fusarium spp., are rising. The increase in IMIs is attributed to various factors, such as transplantation, aggressive treatments, invasive medical devices, and the emergence of new at-risk populations, such as patients with influenza and SARS-CoV-2-associated aspergillosis. The European Organization for Research and Treatment of Cancer and the Mycosis Study Group initially provided definitions based on host and clinical factors, including radiological findings and mycological evidence. The recent 2020 updates of the definitions state that a case confirmed by microscopy, histopathology, and culture from a sterile site is "proven"; however, regarding mycological criteria, this guideline introduced revised thresholds for the galactomannan assay based on sample types, excluded the 1,3-β-D-glucan detection assay, and acknowledged positive Aspergillus polymerase chain reaction tests from serum, plasma, or bronchoalveolar lavage fluid. The current diagnostic approach improves the accuracy and timeliness of diagnosing fungal infections and facilitates more effective patient management.
참고문헌 (39)
- Bongomin F, "Global and multi-national prevalence of fungal diseases-estimate precision", J Fungi(Basel), 3, pp.57~ (2017)
- Lass-Flörl C, "The changing epidemiology of fungal infections", Mol Asp Med, 94, pp.101215~ (2023)
- Drgona L, "Clinical and economic burden of invasive fungal diseases in Europe : focus on preemptive and empirical treatment of Aspergillus and Candida species", Eur J Clin Microbiol Infect Dis, 33, pp.7~21 (2014)
- Lee SO, "Diagnosis and Treatment of invasive mold diseases", Infect Chemother, 55, pp.10~21 (2023)
- Huh K, "Serious fungal infections in Korea", Eur J Clin Microbiol Infect Dis, 36, pp.957~963 (2017)
- Donnelly JP, "Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium", Clin Infect Dis, 71, pp.1367~1376 (2020)
- Schauwvlieghe A, "Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza : a retrospective cohort study", Lancet Respir Med, 6, pp.782~792 (2018)
- Patel A, "Multicenter epidemiologic study of coronavirus disease-associated mucormycosis. India", Emerg Infect Dis, 27, pp.2349~2359 (2021)
- Sung AH, "Patient characteristics and risk factors in invasive mold infections : comparison from a systematic review and database analysis", Clinicoecon Outcomes Res, 13, pp.593~602 (2021)
- Naggie S, "Molds : hyalohyphomycosis, phaeohyphomycosis, and zygomycosis", Clin Chest Med, 30, pp.337~353 (2009)
- Ramirez-Garcia A, "Scedosporium and Lomentospora : an updated overview of underrated opportunists", Med Mycol, 56, pp.S102~S125 (2018)
- Lee R, "Fundamentals of mycology for infection control and prevention", Korean J Healthc Assoc Infect Control Prev, 25, pp.86~99 (2020)
- Bartoletti M, "Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19 : a prospective study", Clin Infect Dis, 73, pp.e3606~e3614 (2021)
- Hoenigl M, "COVID-19-associated fungal infections", Nat Microbiol, 7, pp.1127~1140 (2022)
- De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group(EORTC, Clin Infect Dis, pp.2008, 46[DOI]
- Ascioglu S, "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants : an international consensus", Clin Infect Dis, 34, pp.7~14 (2002)
- Acet-Öztürk NA, "Impact of revised EORTC", MSGERC 2020 criteria on diagnosis and prognosis of invasive pulmonary aspergillosis in patients with hematological malignancies undergoing bronchoscopy, 2022, pp.32, 101304~
- Marr KA, "Combination antifungal therapy for invasive aspergillosis : a randomized trial", Ann Intern Med, 162, pp.81~89 (2015)
- Fang W, "Diagnosis of invasive fungal infections : challenges and recent developments", J Biomed Sci, 30, pp.42~ (2023)
- Kim SH, "Epidemiology and clinical outcomes of invasive pulmonary aspergillosis : a nationwide multicenter study in Korea", Infect Chemother, 44, pp.282~288 (2012)
- Pfeiffer CD, "Diagnosis of invasive aspergillosis using a galactomannan assay : a meta-analysis", Clin Infect Dis, 42, pp.1417~1427 (2006)
- Sanglard D, "Emerging threats in antifungal-resistant fungal pathogens", Front Med, 3, pp.11~ (2016)
- Sulahian A, "False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam", N Engl J Med, 349, pp.2366~2367 (2003)
- Chong E, "False-positive Aspergillus galactomannan immunoassay in the glucose component of total parenteral nutrition products", Microbiol Spectr, 11, pp.e01673-23~ (2023)
- Shin DW, "False-positive results of galactomannan assays in patients administered glucose-containing solutions", Sci Rep, 14, pp.2552~ (2024)
- Clancy CJ, "Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients", J Clin Microbiol, 45, pp.1759~1765 (2007)
- Verweij PE, "Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections", Med Mycol, 36, pp.146~155 (1998)
- Lamoth F, "Assessment of the role of 1, 3-β-D-glucan testing for the diagnosis of invasive fungal infections in adults", Clin Infect Dis, 72, pp.S102~S108 (2021)
- Yoo IY, "Culture-independent diagnostic approaches for invasive aspergillosis in solid organ transplant recipients", Korean J Transplant, 37, pp.155~164 (2023)
- Theel ES, "β-D-glucan testing is important for diagnosis of invasive fungal infections", J Clin Microbiol, 51, pp.3478~3483 (2013)
- Gudisa R, "Nucleic-acidbased molecular fungal diagnostics : a way to a better future", Diagnostics(Basel), 14, pp.520~ (2024)
- White PL, "Aspergillus polymerase chain reaction : systematic review of evidence for clinical use in comparison with antigen testing", Clin Infect Dis, 61, pp.1293~1303 (2015)
- Cruciani M, "Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people", Cochrane Database Syst Rev, 9, pp.CD009551~ (2019)
- Springer J, "Clinical evaluation of a Mucoralesspecific real-time PCR assay in tissue and serum samples", J Med Microbiol, 65, pp.1414~1421 (2016)
- Arastehfar A, "COVID-19 associated pulmonary aspergillosis(CAPA)-from immunology to treatment", J Fungi, 6, pp.91~ (2020)
- Imbert S, "Aspergillus PCR in serum for the diagnosis, followup and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients", Clin Microbiol Infect, 22, pp.562~ (2016)
- Barnes RA, "Diagnosis of aspergillosis by PCR : Clinical considerations and technical tips", Med Mycol, 56, pp.60~72 (2018)
- Kidd SE, "A new age in molecular diagnostics for invasive fungal disease : Are we ready?", Front Microbiol, 10, pp.2903~ (2019)
- White PL, "An overview of using fungal DNA for the diagnosis of invasive mycoses", Expert Rev Mol Diagn, 22, pp.169~184 (2022)